Praxis Precision Medicines, Inc. - Common Stock (PRAX)
37.69
-0.93 (-2.41%)
Praxis Precision Medicines Inc is a biopharmaceutical company focused on developing innovative therapies for individuals suffering from various neurological and psychiatric disorders
The company utilizes a precision medicine approach, leveraging advanced genetic and biomarker research to understand the underlying mechanisms of these conditions, with the goal of creating targeted treatments that address unmet medical needs. By integrating cutting-edge science with a commitment to improving patient outcomes, Praxis seeks to transform the landscape of mental health and neurological care through the discovery and development of novel drug candidates.
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction and improvement in patient behavior and communication.
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
What a day for Meta! I was planning to add to my position, but the volume was too low. I would have been shaken out of most of it for the swing before it could become this position trade.
Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phase 3 results expected in 2024) and PRAX-628 for focal seizures.
